Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies

Table 3

Stability data of brigatinib and brigatinib-analog in rat plasma and brain homogenate under various storage conditions at two QC levels (n = 6).

Analytes	Matrix	Spiked conc. (ng/mL)	Storage conditions (ng/mL)
			Ambient temperature for 6 h	−20°C for 10 d	Three freeze-thaw cycles	Autosampler at 4°C for 24 h
Brigatinib	Plasma	2.0	2.10 ± 0.12	2.05 ± 0.17	1.94 ± 0.09	1.90 ± 0.10
		1600	1585.06 ± 98.31	1719.73 ± 107.09	1678.34 ± 95.87	1645.17 ± 118.52
	Brain homogenate	1.0	1.06 ± 0.08	0.97 ± 0.06	1.02 ± 0.06	0.96 ± 0.05
		800	788.85 ± 69.25	760.29 ± 48.33	847.44 ± 57.65	813.16 ± 72.23
Brigatinib-analog	Plasma	2.0	2.03 ± 0.11	1.95 ± 0.12	2.01 ± 0.09	1.89 ± 0.12
		1600	1638.54 ± 97.76	1705.49 ± 109.83	1578.36 ± 125.20	1582.61 ± 101.88
	Brain homogenate	1.0	1.04 ± 0.05	1.07 ± 0.11	0.98 ± 0.07	0.97 ± 0.06
		800	828.64 ± 66.54	846.09 ± 53.83	833.68 ± 56.59	783.28 ± 32.39